Stockwatch: Don't Fear The Pricing Reaper
The drug pricing debate has tarred many brushes in the pharmaceutical value chain. Whilst politicians may not yet be able to distinguish between the brazen price inflation of generic drugs and the high prices of innovative and recently launched branded drugs, the debate and rhetoric will eventually polarize. That polarization may be helped by new drugs with potentially very high list prices that are destined to be prescribed to very few patients.
Register for our free email digests: